Nasus Pharma Ltd. (NSRX)Healthcare | Drug Manufacturers - General | Tel Aviv-Yafo, Israel | NYSE American
3.16 USD
-0.16
(-4.819%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 3.16 |
Hot Take ↕ | Oct. 10, 2026, 8:29 a.m. EDT
The immediate outlook is flat due to a lack of directional edge, though recent price action shows a modest bounce off the lows. However, the long-term investment case is severely compromised by deteriorating fundamentals and a complete absence of price history for meaningful assessment. The company is burning significant cash, with negative free cash flow and operating cash flow, while posting negative returns on both assets and equity. This financial bleed is exacerbated by a recent leadership crisis, including the resignation of the CEO, which introduces substantial execution risk. Furthermore, the stock trades at a premium to its book value despite generating no earnings, suggesting the market is pricing in a turnaround that has yet to materialize. With no dividend to provide income and a balance sheet showing negative cash generation, the security offers no margin of safety for a long-term holder. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.177668 |
| AutoETS | 0.183312 |
| AutoARIMA | 0.183317 |
| AutoTheta | 0.250808 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 1.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.573 |
| Excess Kurtosis | -0.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.937 |
| Market Cap | 37,015,636 |
| Website | https://www.nasuspharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.57974684 |
| Address1 | Yigal Alon 65 |
| All Time High | 9.99 |
| All Time Low | 1.98 |
| Ask | 3.46 |
| Ask Size | 100 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 24,540 |
| Average Daily Volume3 Month | 16,236 |
| Average Volume | 16,236 |
| Average Volume10Days | 24,540 |
| Bid | 3.1 |
| Bid Size | 1,000 |
| Book Value | 0.939 |
| City | Tel Aviv-Yafo |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.16 |
| Current Ratio | 8.769 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.33 |
| Day Low | 3.1 |
| Debt To Equity | 0.937 |
| Display Name | Nasus Pharma |
| Dividend Yield | 0.0 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 25,291,154 |
| Eps Trailing Twelve Months | -1.2 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.64524 |
| Fifty Day Average Change | -0.48523998 |
| Fifty Day Average Change Percent | -0.13311605 |
| Fifty Two Week Change Percent | -57.974686 |
| Fifty Two Week High | 9.5 |
| Fifty Two Week High Change | -6.34 |
| Fifty Two Week High Change Percent | -0.6673684 |
| Fifty Two Week Low | 1.98 |
| Fifty Two Week Low Change | 1.1800001 |
| Fifty Two Week Low Change Percent | 0.5959596 |
| Fifty Two Week Range | 1.98 - 9.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,755,091,800,000 |
| Float Shares | 5,459,696 |
| Free Cashflow | -6,983,000 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 7 |
| Fullday Change | -0.08990002 |
| Fullday Change Percent | -2.6716995 |
| Fullday Price | 3.16 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.49153 |
| Held Percent Institutions | 0.18358 |
| Implied Shares Outstanding | 11,713,808 |
| Industry | Drug Manufacturers - General |
| Industry Disp | Drug Manufacturers - General |
| Industry Key | drug-manufacturers-general |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel. |
| Long Name | Nasus Pharma Ltd. |
| Market | us_market |
| Market Cap | 37,015,636 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_714524293 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -10,559,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 41,818,294 |
| Number Of Analyst Opinions | 3 |
| Open | 3.22 |
| Operating Cashflow | -10,521,000 |
| Operating Margins | 0.0 |
| Phone | 972 3 573 6632 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.16 |
| Post Market Time | 1,791,934,204 |
| Previous Close | 3.32 |
| Price Hint | 4 |
| Price To Book | 3.3652823 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.417 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.16 |
| Regular Market Change Percent | -4.81927 |
| Regular Market Day High | 3.33 |
| Regular Market Day Low | 3.1 |
| Regular Market Day Range | 3.1 - 3.33 |
| Regular Market Open | 3.22 |
| Regular Market Previous Close | 3.32 |
| Regular Market Price | 3.16 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 13,414 |
| Return On Assets | -0.96730006 |
| Return On Equity | -3.16043 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 11,713,808 |
| Shares Percent Shares Out | 0.0067000003 |
| Shares Short | 78,238 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 87,272 |
| Short Name | Nasus Pharma Ltd. |
| Short Percent Of Float | 0.0119 |
| Short Ratio | 4.24 |
| Source Interval | 15 |
| Symbol | NSRX |
| Target High Price | 22.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 19.66667 |
| Target Median Price | 19.0 |
| Total Cash | 11,818,000 |
| Total Cash Per Share | 1.009 |
| Total Debt | 103,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.940205 |
| Two Hundred Day Average Change | -0.780205 |
| Two Hundred Day Average Change Percent | -0.19801126 |
| Type Disp | Equity |
| Volume | 13,414 |
| Website | https://www.nasuspharma.com |
| Zip | 6,744,317 |